Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | EVP, Chief Commercial Officer | August 31, 2026 | August 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date August 31, 2026 · Filed August 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,555 |
Ending reported balance
After 2026-08-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-31 · Exercise / conversion · Acquired 10,000 · Balance 68,555 Row 2 · 2026-08-31 · Sale · Disposed 10,000 · Balance 58,555 |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.26 · Expires 2031-03-31 | Direct | 0 |
Reported balance
After 2026-08-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-31 · Exercise / conversion · Disposed 10,000 · Balance 0 F1: Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Aug 31, 2026 20:57 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $23.26 | $0.00 |
DisclosureSEC source: 0001061983-26-000090 · form4.xml · derivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2031-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| August 31, 2026 Filed Aug 31, 2026 20:57 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 10,000 | $70.24 | $702,400.00 |
DisclosureSEC source: 0001061983-26-000090 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,555 Read SEC document |
| August 31, 2026 Filed Aug 31, 2026 20:57 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 10,000 | $23.26 | $232,600.00 |
DisclosureSEC source: 0001061983-26-000090 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2026 Filed Jul 30, 2026 20:26 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $23.26 | $0.00 |
DisclosureSEC source: 0001061983-26-000086 · form4.xml · derivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 14,000 shares Expires 2031-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| July 30, 2026 Filed Jul 30, 2026 20:26 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 14,000 | $79.88 | $1,118,320.00 |
DisclosureSEC source: 0001061983-26-000086 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,555 Read SEC document |
| July 30, 2026 Filed Jul 30, 2026 20:26 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 14,000 | $23.26 | $325,640.00 |
DisclosureSEC source: 0001061983-26-000086 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:19 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $23.26 | $0.00 |
DisclosureSEC source: 0001061983-26-000073 · form4.xml · derivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 15,000 shares Expires 2031-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:19 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 15,000 | $85.80 | $1,287,000.00 |
DisclosureSEC source: 0001061983-26-000073 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,555 Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:19 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 15,000 | $23.26 | $348,900.00 |
DisclosureSEC source: 0001061983-26-000073 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2026 Filed Jun 1, 2026 22:51 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $23.26 | $0.00 |
DisclosureSEC source: 0001061983-26-000065 · form4.xml · derivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,000 Underlying: Common Stock · 15,000 shares Expires 2031-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| June 01, 2026 Filed Jun 1, 2026 22:51 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 15,000 | $74.08 | $1,111,200.00 |
DisclosureSEC source: 0001061983-26-000065 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,555 Read SEC document |
| June 01, 2026 Filed Jun 1, 2026 22:51 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 15,000 | $23.26 | $348,900.00 |
DisclosureSEC source: 0001061983-26-000065 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2026 Filed May 5, 2026 20:11 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 11,333 | $0.00 Strike: $39.13 | $0.00 |
DisclosureSEC source: 0001061983-26-000047 · form4.xml · derivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,070 Underlying: Common Stock · 11,333 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2026 Filed May 5, 2026 20:11 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 11,333 | $77.25 | $875,474.25 |
DisclosureSEC source: 0001061983-26-000047 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,555 Read SEC document |
| May 05, 2026 Filed May 5, 2026 20:11 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 11,333 | $39.13 | $443,460.29 |
DisclosureSEC source: 0001061983-26-000047 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 15,857 | $0.00 Strike: $37.63 | $0.00 |
DisclosureSEC source: 0001061983-26-000046 · form4.xml · derivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,857 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 15,857 | $65.00 | $1,030,705.00 |
DisclosureSEC source: 0001061983-26-000046 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,555 Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 15,857 | $37.63 | $596,698.91 |
DisclosureSEC source: 0001061983-26-000046 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2026 Filed Apr 30, 2026 20:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $23.26 | $0.00 |
DisclosureSEC source: 0001061983-26-000045 · form4.xml · derivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 15,000 shares Expires 2031-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| April 30, 2026 Filed Apr 30, 2026 20:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 15,000 | $63.26 | $948,900.00 |
DisclosureSEC source: 0001061983-26-000045 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,555 Read SEC document |
| April 30, 2026 Filed Apr 30, 2026 20:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 15,000 | $23.26 | $348,900.00 |
DisclosureSEC source: 0001061983-26-000045 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2026 Filed Apr 15, 2026 21:29 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 7,449 | $66.02 | $491,782.98 |
DisclosureSEC source: 0001061983-26-000036 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,555 Read SEC document |
| March 31, 2026 Filed Mar 31, 2026 20:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 3,639 | $65.00 | $236,535.00 |
DisclosureSEC source: 0001061983-26-000030 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,004 Read SEC document |
| March 18, 2026 Filed Mar 18, 2026 20:55 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,930 | $62.07 | $119,795.10 |
DisclosureSEC source: 0001061983-26-000025 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,185 Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 21:43 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,916 | $62.15 | $181,229.40 |
DisclosureSEC source: 0001061983-26-000028 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,573 F2 · kind: Company compelled sell-to-cover transaction to satisfy tax withholding obligations attributable to RSU vesting. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 21:43 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,626 | $62.15 | $349,655.90 |
DisclosureSEC source: 0001061983-26-000028 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,489 F1 · kind: Company compelled sell-to-cover transaction to satisfy tax withholding obligations attributable to RSU vesting. Read SEC document |
| March 16, 2026 Filed Mar 16, 2026 21:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,709 | $61.03 | $104,300.27 |
DisclosureSEC source: 0001061983-26-000019 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,149 Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:08 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 29,480 | $0.00 Strike: $60.06 | $0.00 |
DisclosureSEC source: 0001061983-26-000023 · form4.xml · derivative · entry 4 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,480 Underlying: Common Stock · 29,480 shares Expires 2036-03-14 F4 · kind: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:08 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (Right to Buy) · Derivative | 1,665 | $0.00 Strike: $60.06 | $0.00 |
DisclosureSEC source: 0001061983-26-000023 · form4.xml · derivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,665 Underlying: Common Stock · 1,665 shares Expires 2036-03-14 F3 · kind: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:08 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 13,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-26-000023 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,824 F2 · kind: Special supplemental equity award comprised of restricted stock units ("RSUs" that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 50% of the RSUs on the 1-year anniversary of the grant date and 50% of the RSUs on the 2-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:08 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 20,646 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-26-000023 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,504 F1 · kind: Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan. Read SEC document |
| March 09, 2026 Filed Mar 10, 2026 22:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,582 | $60.72 | $156,779.04 |
DisclosureSEC source: 0001061983-26-000018 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,858 F1 · kind: Sell to cover transaction to satisfy company tax withholding obligations upon vesting of RSUs. Read SEC document |
| March 05, 2026 Filed Mar 5, 2026 21:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $23.26 | $0.00 |
DisclosureSEC source: 0001061983-26-000015 · form4.xml · derivative · entry 6 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,000 Underlying: Common Stock · 15,000 shares Expires 2031-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| March 05, 2026 Filed Mar 5, 2026 21:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $39.13 | $0.00 |
DisclosureSEC source: 0001061983-26-000015 · form4.xml · derivative · entry 5 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,403 Underlying: Common Stock · 11,000 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2026 Filed Mar 5, 2026 21:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 15,000 | $23.26 | $348,900.00 |
DisclosureSEC source: 0001061983-26-000015 · form4.xml · nonDerivative · entry 4 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2026 Filed Mar 5, 2026 21:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 11,000 | $61.88 | $680,680.00 |
DisclosureSEC source: 0001061983-26-000015 · form4.xml · nonDerivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,440 Read SEC document |
| March 05, 2026 Filed Mar 5, 2026 21:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 15,000 | $61.87 | $928,050.00 |
DisclosureSEC source: 0001061983-26-000015 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,440 Read SEC document |
| March 05, 2026 Filed Mar 5, 2026 21:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 11,000 | $39.13 | $430,430.00 |
DisclosureSEC source: 0001061983-26-000015 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 21:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 886 | $0.00 Strike: $37.63 | $0.00 |
DisclosureSEC source: 0001061983-26-000013 · form4.xml · derivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 886 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 21:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 886 | $61.62 | $54,595.32 |
DisclosureSEC source: 0001061983-26-000013 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,440 Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 21:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 886 | $37.63 | $33,340.18 |
DisclosureSEC source: 0001061983-26-000013 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 01:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $23.26 | $0.00 |
DisclosureSEC source: 0001061983-26-000012 · form4.xml · derivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,000 Underlying: Common Stock · 15,000 shares Expires 2031-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 01:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 15,000 | $61.93 | $928,950.00 |
DisclosureSEC source: 0001061983-26-000012 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,440 Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 01:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 15,000 | $23.26 | $348,900.00 |
DisclosureSEC source: 0001061983-26-000012 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2026 Filed Feb 2, 2026 21:40 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 886 | $0.00 Strike: $37.63 | $0.00 |
DisclosureSEC source: 0001061983-26-000011 · form4.xml · derivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 886 Underlying: Common Stock · 886 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| February 02, 2026 Filed Feb 2, 2026 21:40 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 886 | $62.10 | $55,020.60 |
DisclosureSEC source: 0001061983-26-000011 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,440 Read SEC document |
| February 02, 2026 Filed Feb 2, 2026 21:40 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 886 | $37.63 | $33,340.18 |
DisclosureSEC source: 0001061983-26-000011 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2026 Filed Jan 5, 2026 21:26 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $23.26 | $0.00 |
DisclosureSEC source: 0001061983-26-000002 · form4.xml · derivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,000 Underlying: Common Stock · 15,000 shares Expires 2031-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2026 Filed Jan 5, 2026 21:26 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 15,000 | $60.28 | $904,200.00 |
DisclosureSEC source: 0001061983-26-000002 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,440 Read SEC document |
| January 05, 2026 Filed Jan 5, 2026 21:26 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 15,000 | $23.26 | $348,900.00 |
DisclosureSEC source: 0001061983-26-000002 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.